A detailed history of First Light Asset Management, LLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, First Light Asset Management, LLC holds 2,575,546 shares of PLRX stock, worth $34.3 Million. This represents 2.52% of its overall portfolio holdings.

Number of Shares
2,575,546
Previous 3,401,213 24.28%
Holding current value
$34.3 Million
Previous $36.6 Million 21.04%
% of portfolio
2.52%
Previous 3.33%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.52 - $14.35 $8.69 Million - $11.8 Million
-825,667 Reduced 24.28%
2,575,546 $28.9 Million
Q2 2024

Aug 14, 2024

SELL
$10.58 - $15.61 $1.42 Million - $2.09 Million
-133,780 Reduced 3.78%
3,401,213 $36.6 Million
Q1 2024

May 15, 2024

SELL
$14.14 - $19.59 $802,911 - $1.11 Million
-56,783 Reduced 1.58%
3,534,993 $52.7 Million
Q4 2023

Feb 14, 2024

BUY
$12.85 - $19.15 $22.9 Million - $34.1 Million
1,781,600 Added 98.42%
3,591,776 $65 Million
Q2 2023

Aug 14, 2023

BUY
$18.12 - $30.56 $6.97 Million - $11.8 Million
384,822 Added 27.0%
1,810,176 $32.8 Million
Q1 2023

May 15, 2023

BUY
$18.73 - $36.26 $6.88 Million - $13.3 Million
367,473 Added 34.74%
1,425,354 $37.9 Million
Q4 2022

Feb 14, 2023

BUY
$17.0 - $25.43 $1.58 Million - $2.36 Million
92,767 Added 9.61%
1,057,881 $20.4 Million
Q3 2022

Nov 14, 2022

BUY
$7.67 - $24.23 $1.5 Million - $4.74 Million
195,744 Added 25.44%
965,114 $20.2 Million
Q2 2022

Aug 12, 2022

BUY
$4.11 - $8.75 $1.47 Million - $3.13 Million
358,042 Added 87.05%
769,370 $6.16 Million
Q1 2022

May 13, 2022

BUY
$7.01 - $14.1 $171,268 - $344,491
24,432 Added 6.31%
411,328 $2.88 Million
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.26 $4.75 Million - $7.06 Million
386,896 New
386,896 $5.22 Million

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $647M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track First Light Asset Management, LLC Portfolio

Follow First Light Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Light Asset Management, LLC with notifications on news.